Menu Search
Equities

Cytori Cell Research Institute Inc

3750:TYO

Cytori Cell Research Institute Inc

Actions
Real EstateReal Estate Investment and Services
  • Price (JPY)954.00
  • Today's Change-1.00 / -0.10%
  • Shares traded14.40k
  • 1 Year change+0.85%
  • Beta0.6228
Data delayed at least 20 minutes, as of Jul 26 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cytori Cell Research Institute Inc is a Japan-based company mainly engaged in the real asset business. The Company operates through two segments. The Real Asset segment is engaged in the purchase and sales of real estate and investment of real estate business related projects, as well as development, renovation and opening of hotels, and operation of hotels. The Medical segment is engaged in the investment of regenerative medicine business centered on cell therapy services, as well as sales of medical equipment and consumables. The main products include Celusion centrifuge and the Celusion cell therapy kit.

  • Revenue in JPY (TTM)1.56bn
  • Net income in JPY138.16m
  • Incorporated2004
  • Employees16.00
  • Location
    Cytori Cell Research Institute Inc7FOtemachi Park Bldg., 1-1-1, Ote-machiCHIYODA-KU 100-0004JapanJPN
  • Phone+81 368605701
  • Fax+81 368605702
  • Websitehttps://cytori.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.